Comorbidity of chronic obstructive pulmonary disease and cardiovascular diseases: Place of therapy with modern β-adrenoblockers

Abstract

Chronic obstructive pulmonary disease (COPD) is the fourth largest cause of worldwide mortality. Presence of comorbidities is registered in 96% of COPD patients. The most important of these are cardiovascular diseases (coronary artery disease, arterial hypertension, chronic heart failure), which contribute to COPD patients’ mortality in every third case. COPD and cardiovascular diseases have common risk factors and pathogenetic mechanisms. Cardioselective β-blockers reduce mortality risk and frequency of COPD exacerbation, are effective and safe in treatment of COPD patients.